On or Off Target: Mutations, Models, and Predictions

See allHide authors and affiliations

Science Translational Medicine  09 Jun 2010:
Vol. 2, Issue 35, pp. 35ps28
DOI: 10.1126/scitranslmed.3001263

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


In a series of articles published in February 2010, The New York Times chronicled, from a personal perspective, the rollercoaster experience of those associated with clinical trials of a RAF inhibitor for the treatment of melanoma. In this issue of Science Translational Medicine, Whittaker et al. describe research that reconciles some of the bewildering aspects of the discovery and development of drugs that inhibit such protein kinase targets in cancer.


  • Citation: L. A. Garraway, W. C. Hahn, On or off target: Mutations, models, and predictions. Sci. Transl. Med. 2, 35ps28 (2010).

View Full Text

Stay Connected to Science Translational Medicine